Effects of Muscular Dystrophy reversed by gene therapy, reports team fromChildren's National Medical Center and the University of Pittsburgh

October 22, 1999

SAN FRANCISCO, Oct. 19 -- Animal muscles crippled due to a form of muscular dystrophy can be repaired, both in size and strength, through an innovative gene therapy, according to a team of investigators from the Children's National Medical Center in Washington, D.C., and the University of Pittsburgh. The results, presented Friday, Oct. 22, at the annual meeting of the American Society of Human Genetics (ASHG) in San Francisco, offer the first evidence that whole muscles can be functionally rescued in any type of muscular dystrophy using an extremely safe gene vector.

"We are very excited by these preliminary results, which suggest that we can use a non-toxic virus to safely shuttle a gene for an important muscle protein that is improperly made in people suffering limb girdle muscular dystrophy," said Devin Dressman, who is presenting the results and who is a graduate student at the Center for Genetic Medicine, Children's National Medical Center, and the University of Pittsburgh's School of Medicine. "These findings demonstrate the feasibility of using the gene therapy approach in treating affected patients."

In their experiments, the investigators used a non-replicating adeno-associated virus (AAV) to carry a gene for the sarcoglycan protein, an important constituent of skeletal muscle. Unlike several other available viral vectors, AAV does not provoke an immune response from the body, either by itself or when it resides within cells. Furthermore, it can infect non-dividing cells and it takes up residence permanently, thus allowing long-term production of a critical protein.

In a collaborative effort, Xiao Xiao, Ph.D., assistant professor of molecular genetics and biochemistry at the University of Pittsburgh, injected this AAV-sarcoglycan gene combination into hamster leg muscles ravaged by limb girdle dystrophy. After one month, Jon Watchko, M.D., associate professor of pediatrics and of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh, tested the treated muscles and found that they increased nearly 100 percent in strength and resumed normal size.

Limb girdle muscular dystrophy affects several thousand people in the United States, causing rapid degeneration of the large muscles attached to the shoulders and hips. Currently no effective treatment exists for this fatal disorder. The Children's/Pitt team of investigators is currently planning a gene therapy treatment protocol based on the experimental findings. This approach may be applied to other forms of muscular dystrophy as well, such as the more common lethal condition, Duchenne muscular dystrophy, which affects 20,000 boys in this country and is considered one of the most prevalent diseases to result from a single gene defect.

Mr. Dressman is presenting the research findings as part of an ASHG press briefing on gene therapy at 7 p.m., EST, Friday, Oct. 22, in San Francisco.
-end-
Contact: Lauren Ward or Kathryn Duda
Phone: 412-624-2607
Fax: 412-624-3184
E-mail:
wardle@msx.upmc.edu
dudak@msx.upmc.edu

University of Pittsburgh Medical Center

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.